Overview

Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With Hip OA Compared to Intra-articular Steroid Injections

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
0
Participant gender:
All
Summary
This will be a multi-center, prospective, single-blinded randomized clinical trial to investigate the effectiveness of using cooled radiofrequency ablation (CRFA) for the treatment of osteoarthritis (OA) hip pain and function in subjects treated with CRFA compared with standard of care intra-articular steroid injections
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Rothman Institute Orthopaedics
Criteria
Inclusion Criteria:

1. Male or female subjects older than 18 years of age presenting with radiographic
evidence of hip OA and demonstrating hip pain for at least 30 days (Radiographic
evidence of hip OA is defined as Kellegran-Lawrence grade 2-4)

2. Relief of patients' typical hip pain symptoms after a positive diagnostic nerve block
test and eligibility for cooled radiofrequency ablation of these same nerves

Exclusion Criteria:

1. Patients who have received any steroid injection in hip within the last 90 days

2. Individuals who cannot consent for themselves such as children and subjects with
impaired decision making

3. Local infection at injection site or active systemic infection

4. Anticoagulation status with inability to discontinue medication for appropriate
duration for nerve blocks and CRFA given proximity to major artery. (No
anticoagulation contraindications for joint injection)

5. Automated implantable cardioverter defibrillator with inability to utilize magnet for
CRFA per treating cardiologist

6. Body habitus does not allow for placement of longest needles and electrodes
(approximately 15cm) to successfully administer treatment

7. Allergy or severe renal impairment precluding iodinated contrast or magnevist
injection despite standard premedication protocol

8. Negative diagnostic nerve block tests